Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Moberg discontinues actinic keratosis drug development
Moberg Derma president and CEO Peter Wolpert said the commercial potential of the project is believed to be decreased based on the completed study and thus continued investment
Moberg Derma president and CEO Peter Wolpert said the commercial potential of the project is believed to be decreased based on the completed study and thus continued investment
The agreement aims to manufacture eribulin mesylate as well as other developmental drugs. DSM Pharmaceutical Products president and CEO Alexander Wessels said, "We are delighted to be working
Under the partnership, Crystal Pharmatech combines its expertise with Particle Sciences advanced drug delivery solutions compounds to offer clients an optimal solution for developing low solubility pharmaceutical compounds.
The study, which was conducted by Novum Pharmaceutical Research Services, measured the amount of ketoprofen found in the bloodstream following topical application of two different doses of the
According to the deal, Heptares will produce stabilized receptors (StaRs) for MorphoSys proposed GPCR disease target set. The Ylanthia antibody library will then be applied by MorphoSys to
Under the agreement, Boehringer will implement ChemAxon’s chemistry software platform for use in multiple applications across research and development, supporting in-house activities and work with external collaboration partners.
Rayos is a proprietary delayed-release formulation of low-dose prednisone and is known as Lodotra outside the US. Horizon Pharma chairman, president and chief executive officer Timothy Walbert said
The acquired products include drugs for the treatment of dermatology, respiratory and autoimmune diseases. Innovus said as none of the drugs are currently being marketed, the company is
Shared laboratory, concept lab, offers entrepreneurs access to single bench spaces for early stage research prior to committing additional capital. Open collaboration space, an open-plan office setting, offers
The adeno-associated virus based human gene therapy Glybera developed by uniQure is indicated for the orphan disease lipoprotein lipase deficiency (LPLD). Xenon president and CEO Simon Pimstone said,